Artificial intelligence matches dermatologists in melanoma diagnosis
1. Artificial intelligence triage for melanoma shows more than 90 percent sensitivity and is now in trials within the National ...
1. Artificial intelligence triage for melanoma shows more than 90 percent sensitivity and is now in trials within the National ...
Google’s AI matches dermatologists in melanoma diagnosis England’s health service is piloting an artificial intelligence tool called Deep Ensemble for ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. FDA ...
1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the ...
1. Intracranial objective response rate was 51% with ipilimumab plus nivolumab and 20% with nivolumab alone. 2. Treatment-related grade 3 ...
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in ...
Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.